Table 10.6i

Immunosuppression Use for Antirejection Treatment from Transplant

to One Year Following Transplantation, 1996 to 2005

Recipients with Intestine Transplants

  Year of Transplant
1996 1997 1998 1999 2000 2001 2002 2003 2004 2005
Transplants 45 68 70 73 82 112 107 116 152 176
Tx with Antirejection Treatments 28 46 24 34 45 41 48 66 59 58
Antibodies Any in Category 25.0% 17.4% 20.8% 47.1% 48.9% 36.6% 31.3% 37.9% 45.8% 39.7%
ALG 3.6% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Atgam/NRATG/NRATS 3.6% 0.0% 4.2% 0.0% 0.0% 2.4% 2.1% 0.0% 3.4% 3.4%
OKT3 17.9% 17.4% 12.5% 44.1% 31.1% 34.1% 29.2% 27.3% 33.9% 22.4%
Thymoglobulin 0.0% 0.0% 0.0% 11.8% 17.8% 7.3% 6.3% 3.0% 13.6% 10.3%
Zenapax 0.0% 0.0% 4.2% 5.9% 6.7% 0.0% 2.1% 1.5% 1.7% 3.4%
Simulect 0.0% 0.0% 0.0% 0.0% 6.7% 0.0% 0.0% 0.0% 0.0% 0.0%
Campath 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 8.3% 15.2% 6.8% 3.4%
Corticosteroids Any in Category 92.9% 93.5% 91.7% 85.3% 75.6% 80.5% 95.8% 92.4% 93.2% 86.2%
Steroids 92.9% 93.5% 91.7% 85.3% 75.6% 80.5% 95.8% 92.4% 93.2% 86.2%
Antimetabolites Any in Category 3.6% 0.0% 0.0% 0.0% 0.0% 2.4% 0.0% 0.0% 0.0% 1.7%
Cytoxan 3.6% 0.0% 0.0% 0.0% 0.0% 2.4% 0.0% 0.0% 0.0% 1.7%
Methotrexate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%


Source: OPTN/SRTR Data as of May 1, 2007.

Individual drug percentages will not necessarily add up to the drug category percentages, as patients may be prescribed more than one drug within the same category.